Editas Medicine, Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Editas Medicine is in Stage 3, the topping phase, now in week 5 (since Sep 21, 2026). It closed at $2.49, 33.6% below its 52-week high and below its 200-day average, which is rising.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. More about the company

$2.49

-0.40% today

$382M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is EDIT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 54w

S2 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 5w → S1 1w → S4 9w → S1 2w → S2 8w → S3 3w → S4 54w → S1 4w → S4 8w → S1 6w → S2 19w → S3 7w → S4 10w → S1 6w → S2 8w → S3 4w → S2 1w → S3 3w → S2 4w → S3 5w current

Total tracked: 165 weeks across 20 stage runs.

EDIT among Biotechnology304th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…304	EDITEditas Medicine, Inc.	Stage 3 · wk 5	30	−7.4%

vs 52W High

-33.6%

$1.67 lo$3.75 hi

33.6% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 5

1w13w26w

Week 5, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-6.6%

200 DMA: $2.67 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.38x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-7.4%

-4.2%

-22.4%

YTD

+21.5%

-35.8%

Scan Membership

Breakout Watch

Latest: 2023-12-14

6 appearances in last 60 days. First seen: 2019-08-21.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 5 · Vol 0.38x

2026-10-21S3

Wk 5 · Vol 0.34x

2026-10-20S3

Wk 5 · Vol 0.80x

2026-10-19S3

Wk 5 · Vol 0.71x

2026-10-16S3

Wk 4 · Vol 0.54x

2026-10-15S3

Wk 4 · Vol 0.65x

2026-10-14S3

Wk 4 · Vol 0.99x

2026-10-13S3

Wk 4 · Vol 0.87x

2026-10-12S3

Wk 4 · Vol 0.46x

2026-10-09S3

Wk 3 · Vol 1.12x

2026-10-08S3

Wk 3 · Vol 2.27x

2026-10-07S3

Wk 3 · Vol 0.85x

Moving averages & range

50 DMA

$2.79

200 DMA

$2.67

52W High

$3.75

52W Low

$1.67

5D Low

$2.35

Resistance levels (recent highs)

20d High

$2.90

60d High

$3.30

120d High

$3.75

250d High

$3.75

Next resistance

+16.5%

to 20d High

ROE

-118.8%

Profit margin -157.3%

Dividend Yield

0.00%

P/B 3.6

Editas Medicine: quick answers

What stage is Editas Medicine in?

As of Oct 22, 2026, Editas Medicine (EDIT) is in Stage 3, the topping phase. It entered Stage 3 on Sep 21, 2026 and is in week 5. What the four stages mean

Is Editas Medicine in an uptrend?

Its uptrend has stalled. Editas Medicine is in Stage 3, the topping phase that follows an advance. It trades 6.6% below its 200-day average, which is rising.

How far is Editas Medicine from its 52-week high?

Editas Medicine closed at $2.49 on Oct 22, 2026, 33.6% below its 52-week high of $3.75. Its 52-week low is $1.67.

How has Editas Medicine performed over the past year?

As of Oct 22, 2026, Editas Medicine is down 35.8% over the past year and up 21.5% so far in 2026.

Which sector and industry is Editas Medicine in?

Editas Medicine is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.